Intec Pharma to explore Accordion Pill for cannabinoids

JERUSALEM — Intec Pharma, a clinical stage biopharmaceutical company that has developed drugs around its proprietary Accordion Pill technology, announced Thursday that it would initiating a clinical development program for the Accordion Pill platform with cannabinoids. The company said it would formulate and test cannabidiol (CBD) and tetrahydrocannabinol (THC) to treat various indications, among them pain management, during the first quarter of 2017. 

 

An Accordion Pill of THC or CBD could address such drawbacks of current methods of use, including a short duration of effect, delayed onset, dose variability, and adverse events correlated with peak levels, among others, the company said.

 

“We are excited to be expanding our development work to include cannabinoid-based therapies. Current methods of use and treatment with cannabis and cannabinoids are short-acting, which leads to a variety of therapeutic obstacles and gives rise to the need to improve the efficacy and safety of cannabinoids as therapeutics,” Intec Pharma CEO Zeev Weiss said. “We believe our Accordion Pill offers a unique opportunity to provide a long-acting oral therapy of cannabinoids for various indications. We believe that utilizing our proprietary platform technology may significantly extend the absorption phase for CBD and THC, thereby resulting in a prolonged and consistent therapeutic effect.”